Clinical Trial Update: Treatment of Diabetic Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg) [Phase 1]

View source ↗

Summary

This report documents the termination of a Phase 1 open-label study evaluating anecortave acetate sterile suspension (15 mg) for diabetic retinopathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Retinopathy

Drugs mentioned

• anecortave acetate (anecortave acetate)

Snippet

Sponsor: Manhattan Eye, Ear & Throat Hospital | Conditions: Diabetic Retinopathy | Phase 1 | Status: TERMINATED